Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan-amoxicillin dual therapy with or without probiotics versus bismuth quadruple therapy in Helicobacter pylori infection among patients with type 2 diabetes mellitus
ChiCTR2400083573Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of vonoprazan, amoxicillin, esomeprazole, clarithromycin, colloidal bismuth pectin and 1 more in Helicobacter pylori infection (4 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Eradication rate. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
vonoprazanamoxicillinesomeprazoleclarithromycincolloidal bismuth pectin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2400083573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083573.